H-1.1 - Act respecting Héma-Québec and the biovigilance committee

Section 54.1 Disposition versions

2013-06-05

54.1. In this chapter, unless the context indicates otherwise,

“bodily injury” means any physical or mental injury suffered by a victim, including death but excepting any adverse effects determined by regulation;

“Héma-Québec product” means any product distributed by Héma-Québec, except

(1)  when such a product is used for research or clinical trials, unless the Minister decides otherwise; or

(2)  when such a product is made from a human biological product determined by the Government and the Government has decided to exclude it from the compensation plan for victims;

“victim” means a person who received a Héma-Québec product, a person who contracted a disease from a person who received a Héma-Québec product, or a child conceived and born alive and viable of either of such persons or, if death occurs, the person who is entitled to a death benefit.

2009, c. 45, s. 4; 2013, c. 11, s. 14.

2011-05-31

54.1. In this chapter, unless the context indicates otherwise,

“bodily injury” means any physical or mental injury suffered by a victim, including death but excepting any adverse effects determined by regulation;

“Héma-Québec product” means any product distributed by Héma-Québec, except products used for research or clinical trials, unless the Minister decides otherwise;

“victim” means a person who received a Héma-Québec product through a transfusion or graft, a person who contracted a disease from a person who received a Héma-Québec product, or a child conceived and born alive and viable of either of such persons or, if death occurs, the person who is entitled to a death benefit.

2009, c. 45, s. 4.